CD5: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 41: | Line 41: | ||
Aberrant expression of CD5 by B-ALL (rare) or AML (around 10%) is described, but in both cases CD5 expression appears less common compared with other “ambiguous markers”. | Aberrant expression of CD5 by B-ALL (rare) or AML (around 10%) is described, but in both cases CD5 expression appears less common compared with other “ambiguous markers”. | ||
---- | |||
<span style="color:navy">'''''SUMMARY TABLES'''''</span> | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;" | |||
|- | |||
!colspan="7"|<span style="font-size:100%">'''CD13 expression: primitive cell types'''</font> | |||
|- | |||
! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[ETP ALL|i]]''') !! MPAL '''[[MPAL|i]] || Hgns '''[[Hgns|i]]''' | |||
|- | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|- | |||
|} | |||
<span style="font-size:90%">'''Notes:''' xxxxx </span> | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;" | |||
|- | |||
!colspan="8"|'''CD13 expression: mature B cell neoplasms''' | |||
|- | |||
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL | |||
|- | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 14.25%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|- | |||
|} | |||
<span style="font-size:90%">'''Notes:''' xxxxx </span> | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 71.4%; height 40px;" | |||
|- | |||
!colspan="7"|'''CD13 expression: mature T cell neoplasms*''' | |||
|- | |||
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL | |||
|- | |||
|style="width: 20%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 20%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 20%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 20%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|style="width: 20%; background: #FFE4E1 #E6FAFF #66e0ff #00b8e6 #006699; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100% | |||
|- | |||
|} | |||
<span style="font-size:90%">'''Notes:''' xxxxx </span> | |||
---- | ---- | ||
<span style="color:navy">'''''SUMMARY TABLES'''''</span> | <span style="color:navy">'''''SUMMARY TABLES'''''</span> |
Revision as of 17:39, 30 April 2023
- Summary
- This marker is expressed by normal T cells and a subset of normal B cells, however it main diagnostic role is in diagnosis of certain B cell disorders:
- In mature B cell neoplasms CD5 is used to indicate likely CLL or MCL (both have consistent expression of CD5)
- In acute lymphoblastic leukaemia CD5 is useful to indicate T lineage, with (relatively) low levels of aberrant expression
- It has low frequency of expression on other lymphoma types.
Normal expression and function
CD5 binds to the B-cell ligand CD72, and has a negative effect on T and B cell receptor signalling raising the threshold for response to antigen (possibly limiting responses to self-antigens). It is a pan T cell antigen (present on thymocytes and mature T cells) that is also expressed on a subset of B cells (B1 subset comprising around 10% of adult B cells, but with a wide range according to age and disease state). CD5 is expressed at higher level on T cells than B cells, and expression is increased on activation.
Diagnostic role
- CD5 is expressed by almost all cases of CLL/SLL and the majority of cases of mantle cell lymphoma (90%)
- However, CD5 can be expressed by marginal zone lymphoma (15%); lymphoplasmacytoid lymphoma (5-10%); and occasionally diffuse large B cell lymphomas (10%) (where it may be associated with poorer prognosis and Activated B Cell (ABC) subtype).
- CD5 is expressed by most mature T cell neoplasms (with the exception of hepatosplenic T Cell lymphoma and T cell large granular lymphocytic leukaemia).
- CD5 is useful in the diagnosis and classification of T cell acute lymphoblastic leukaemia (T-ALL) since it is positive in 90% of T-ALL, although expression may be dim or absent in early precursor T ALL.
Other relevant information:
Aberrant expression of CD5 by B-ALL (rare) or AML (around 10%) is described, but in both cases CD5 expression appears less common compared with other “ambiguous markers”.
SUMMARY TABLES
CD13 expression: primitive cell types | ||||||
---|---|---|---|---|---|---|
AML | B ALL | Burkitt | T ALL | ETP ALL (i) | MPAL i | Hgns i |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
CD13 expression: mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
CD13 expression: mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
SUMMARY TABLES